Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Estcourt, Lise J ^a   Fortin, Patricia M ^a   Hopewell, Sally ^b   Trivella, Marialena ^b   Hambleton, Ian R ^c   Cho, Gavin ^d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; ANTISICKLING AGENT;

BIBLIOGRAPHIC DATABASE; CHRONIC CHEST COMPLICATION; CHRONIC LUNG DISEASE; CHRONIC SICKLE LUNG DISEASE; CINAHL; CLINICAL ASSESSMENT; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DATA COLLECTION METHOD; DATA EXTRACTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SC DISEASE; HUMAN; IRON OVERLOAD; LONG TERM CARE; MEDLINE; MORTALITY; OUTCOME ASSESSMENT; PEER REVIEW; PRIORITY JOURNAL; PUBLISHING; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; SYSTEMATIC REVIEW; THORAX DISEASE; THORAX RADIOGRAPHY; ACUTE CHEST SYNDROME; COMPLICATION; FEMALE; HYPERTENSION, PULMONARY; MALE;

ACUTE CHEST SYNDROME; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; HYDROXYUREA; HYPERTENSION, PULMONARY; MALE;

EID: 84969555986     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008360.pub4     Document Type: Review

References (58)

1. Atilla E, Topcuoglu P, Yavasoglu S, Karakaya A, Gencturk C, Bozdag S, Arslan O. A randomized comparison of hemoglobin content-based vs standard (unit-based) RBC transfusion policy efficiencies. Vox Sanguinis 2011; Vol. 101, issue S2:121. Abstract No. P-303.
2. Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza L, Castro O, Naeije R, Sood N, Swerdlow PS, Hildesheim M, Gladwin MT, on behalf of the ASSET study group. Exercise capacity and hemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: rResults of the ASSET studies. British Journal of Haematology 2010;149(3):426-35.
3. Chueamuangphan N, Patumanond J, Wongtheptien W, Nawarawong W, Sukonthasarn A, Chuncharunee S, et al. Benefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertension. International Journal of General Medicine 2014;7:411-16.
4. Detterich JA, Kato RM, Rabai M, Meiselman HJ, Coates TD, Wood JC. Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease. Blood 2015;126(6):703-10.
5. Lunt A, McGheea E, Robinsona P, Rees D, Height S, Greenougha A. Lung function, transfusion, pulmonary capillary blood volume and sickle cell disease. Respiratory Physiology & Neurobiology 2016;222:6-10.
6. NCT00023296 Nitric oxide and transfusion therapy for sickle cell patients with pulmonary hypertension. ClinicalTrials.gov NCT00023296 (accessed 28 April 2016).
7. Styles LA, Abboud M, Larkin S, Lo, Kuypers FA1. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. British Journal of Haematology 2006;136(2):343-44.
8. Styles L, Wager CG, Labotka RJ, Smith-Whitley K, Thompson AA, Lane PA, et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). British Journal of Haematology 2012;157(5):627-36.
9. Adams RJ, McKie VC, Brambilla D, Carl E, Gallagher D, Nichols FT, et al. Stroke prevention trial in sickle cell anemia. Controlled Clinical Trials 1998;19(1):110-29. [PUBMED: 9492971]
10. Alhashimi D, Fedorowicz Z, Alhashimi F, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007843.pub2]
11. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Archives of Disease in Childhood 2015;100(1):48-53. [10.1136/ archdischild-2013-303773]
12. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology 2013;2013:439-46.
13. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Whesthoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122(6):1062-71.
14. Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. American Journal of Medicine 1982;73(6):814-21. [PUBMED: 7148875]
15. Davies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M. Red cell alloimmunization in sickle cell disease. British Journal of Haematology 1986;63(2):241-5. [PUBMED: 3087406]
16. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions Version. 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
17. US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute Expert Panel Report 2014. Evidence-based management of sickle cell disease: Expert Panel Report, 2014. http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines (accessed 01 August 2015).
18. Gordeuk VR, Castro OL, Machado R. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood 2016;127(7):820-8.
19. Gravitz L, Pincock S. Sickle-cell disease. Nature 2014;515:S1.
20. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa. A neglected cause of early childhood mortality. American Journal of Preventive Medicine 2011;41(6S4):S398-S405.
21. Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. Journal of Clinical Investigation 1997;99(11):2561-4. [PUBMED: 9169483]
22. Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
23. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
24. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaborartion, 2011. Available from www.cochrane-handbook.org.
25. Higgins JPT, Deeks JJ, Altman DG on behalf of the Cochrane Statistical Methods Group (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0[updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
26. Josephson Cassandra D, Su Leon L, Hillyer Krista L, Hillyer Christopher D. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews 2007;21:118-32.
27. Khoury RA, Musallam KM, Mroueh S, Abboud MR. Pulmonary complications of sickle cell disease. Hemoglobin 2011;35(5-6):625-35.
28. Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. American Journal of Respiratory and Critical Care Medicine 2006;173(11):1264-9.
29. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
30. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British Journal of Haematology 2005;130(3):445-53. [PUBMED: 16042696]
31. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Goldsmith JC, Woolson R, et al. Safety and efficacy of sildenafil therapy for doppler-defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the walk-PHaSST clinical trial. 51st American Society of Hematology Annual Meeting and Exposition. 2009.
32. Mehari A, Klings ES. Chronic pulmonary complications of sickle cell disease. Chest 2016 Jan 13 [Epub ahead of print].
33. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-Analyses:the PRISMA statement. Annals of Internal Medicine 2009;151(4):264-9.
34. Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003426.pub3]
35. NICE (National Institute for Health and Care Excellence). Sickle cell disease. http://cks.nice.org.uk/sickle-cell-disease (accessed 01 August 2015).
36. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
37. Piel F B, Patil A P, Howes R E, Nyangiri O A, Gething P W, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2012;381:142-51.
38. Pleasants S. Epidemiology: a moving target. Nature 2014;515:S2-3.
39. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. ASH Education Program Book 2013;1:447-56.
40. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988;67(1):66-76. [PUBMED: 3336282]
41. Rees D C, Williams T N, Gladwin M T. Sickle-cell disease. Lancet 2010;376:2018-31.
42. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
43. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76(7):1431-7. [PUBMED: 2207318]
44. Scheunemann L P, Ataga K I. Delayed hemolytic transfusion reaction in sickle cell disease. The American Journal of the Medical Sciences 2010;339:266-9.
45. Schmalzer E A, Lee J O, Brown A K, Usami S, Chien S. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987;27:228-33.
46. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochranehandbook.org.
47. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
48. Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0[updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
49. Stovold E, Beecher D, Foxlee R, Noel-Storr A. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Systematic Reviews 2014;3:54.
50. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8(16):[DOI: 10.1186/1745-6215-8-16].
51. Ubesie A, Emodi I, Ikefuna A, Ilechukwu G, Ilechukwu G. Prevalence of human immunodeficiency virus transmission among transfused children with sickle cell anemia in Enugu Nigeria. Annals of Medical and Health Sciences Research 2012;2:109-13.
52. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. New England Journal of Medicine 1990;322(23):1617-21.
53. Vichinsky EP, CM Haberkern, L Neumayr, AN Earles, D Black, M Koshy, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. New England Journal of Medicine 1995;333:206-13.
54. Vij R, Machado RF. Pulmonary complications of hemoglobinopathies. Chest 2010;138(4):973-83.
55. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312(10):1033-48.
56. Cho G, Hambleton IR. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD008360]
57. Cho G, Hambleton IR. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD008360.pub2]
58. Cho G, Hambleton IR. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD008360.pub3]